

開放式退休基金名稱
Open Pension Fund Name

康健護理基金 (澳門) Healthcare Fund (Macau)

基金編號
Fund Code

SHK405
SMO405

投資目標及策略 Investment Objectives and Policies

• 本基金是為放眼於較長線的投資，又願意承擔投資價值出現波動的風險以達至長期回報的投資者而設，旨在提供中至長期資本增長。本基金旗下投資項目擬分散投資於任何認可證券交易所上市公司的康健護理或相關行業的公司的股票相關投資及股份，以及債券及/或貨幣市場工具；而亦可包括存款、固定收益金融工具及有關的投資，及其他准許投資。

• 本基金資產組合的投資範圍和策略基準如下：

資產類別	可容許的投資範圍	策略基準
股票	50% - 70%	65%
債券	20% - 40%	35%
現金	0 - 10%	0%

• 本基金的投資有可能超出所訂定的比重限額，尤其是當在被動的情況下金融資產升值或貶值或資本的流入及流出時，又或者由於金融市場過高的波動而選擇用流動性資產作為避難所（包括銀行存款及現金市場工具），但應僅在合理的期限內超出限額。

• The Fund is designed for investors who hold a longer-term investment view, and are willing to accept the risk to have fluctuations in investment value and seek long-term returns, with the aim of providing medium-to-long-term capital growth. Investment under the Fund are intended to be diversified across equity-related investments and shares in any companies listed on recognized securities exchanges that operate in the healthcare or related industries, as well as bonds and/or money market instruments. Such investment projects may also include deposits, fixed income instruments or related investments, and other permissible investments.

• The investment scope and strategy benchmark of its asset portfolio are as follows:

Asset Class	Permissible Investment Scope	Strategy Benchmark
Equity	50% - 70%	65%
Bond	20% - 40%	35%
Cash	0 - 10%	0%

• Investments of the Fund may go beyond the weighting listed above, particularly in passive scenarios such as appreciation or depreciation of financial assets or capital inflow and outflow, or due to excessive market volatility leading to the use of liquidity assets as a safe haven (including bank deposits and cash market instruments), but such investments shall only exceed the limit within a reasonable period.

基金資料 Fund Information

基金管理實體 Management Company	宏利人壽保險(國際)有限公司 ¹ Manulife (International) Limited ¹
投資顧問 Investment Advisor	宏利投資管理(香港)有限公司 Manulife Investment Management (Hong Kong) Limited
受寄人 Depository	滙豐機構信託服務(亞洲)有限公司 HSBC Institutional Trust Services (Asia) Limited
推出日期(日/月/年) Launch Date (DD/MM/YYYY)	02/01/2014
基金種類 Fund Descriptor	混合資產基金 Balanced Fund
總費用比率 ² Total Expense Ratio ²	1.42%
資產淨值 (百萬元澳門元) Net Asset Value (Million MOP)	17.63
風險程度 Fund Risk Level	中至高 Medium to High
風險/回報指標 ³ Risk / Return Metric ³	4
基金風險標記 ⁴ Fund Risk Indicator ⁴	8.60%
額外風險提示 ⁵ Additional Risk Reminder ⁵	無 / Nil
基金價格 (港元/澳門元) Fund Price (HKD/ MOP)	16.991 / 17.501

基金表現⁶ Fund Performance⁶

累積回報 Cumulative Return (%)	年初至今	三個月	一年	三年	五年	十年	推出至今
	YTD	3 Months	1 Year	3 Years	5 Years	10 Years	Since launch
港元 HKD	6.12%	3.55%	-2.00%	20.15%	24.61%	59.18%	69.91%
澳門元 MOP	6.12%	3.56%	-2.00%	20.16%	24.62%	59.19%	69.91%
年率化回報 Annualized Return (%)	一年	三年	五年	十年	推出至今		
	1 Year	3 Years	5 Years	10 Years	Since launch		
港元 HKD	-2.00%	6.31%	4.50%	4.76%	4.62%		
澳門元 MOP	-2.00%	6.31%	4.50%	4.76%	4.62%		
曆年回報 Calendar Year Return (%)	2020	2021	2022	2023	2024		
	2020	2021	2022	2023	2024		
港元 HKD	7.25%	12.61%	-5.11%	4.80%	0.24%		
澳門元 MOP	7.25%	12.61%	-5.11%	4.80%	0.24%		

資產分佈⁷ Asset Allocation⁷

藥物製造股票 Pharmaceuticals Equities	34.0%
債券 Bonds	29.7%
醫療設備股票 Medical Equipment Equities	15.9%
生物科技股票 Biotechnology Equities	5.6%
藥物零售商股票 Drug Retailers Equities	4.3%
康健護理管理服務股票 Health Care Management Services Equities	3.7%
其他 Others	2.5%
醫療供應股票 Medical Supplies Equities	2.3%
現金 Cash	2.0%

基金十大投資項目⁸ Fund Top 10 Portfolio Holdings⁸

證券 Securities	持有量 Holdings (%)
1. Eli Lilly and Co.	6.49%
2. Johnson & Johnson	4.37%
3. AbbVie Inc.	4.11%
4. AstraZeneca PLC	4.05%
5. Medtronic Plc	3.52%
6. Stryker Corp.	3.42%
7. McKesson Corp.	3.20%
8. Abbott Laboratories Ltd.	2.82%
9. UCB S.A.	2.52%
10. Amgen Inc.	2.49%

基金評論 Fund Commentary

- 環球股市 9 月份表現理想，在普遍利好消息帶動下延續年初至今的強勁升勢，並推動環球主要指數屢創歷史新高。投資情緒持續高漲，反映環球正增長、企業盈利穩健，以及美國聯儲局與其他央行減息的利好因素交織。美國成為正回報的主要推動因素，科技業因人工智能熱潮持續而表現尤為突出。此外，美國聯儲局減息 25 個基點，使市場對來年進一步減息的預期升溫。海外市場升幅較窄。歐洲雖錄得正回報，但表現遜於美國，主要受德國表現低迷拖累。亞洲已發展市場同樣表現落後，整體回報平淡。另一方面，新興市場則顯著造好，表現大幅領先已發展市場，部份受惠於中國市場的強勁升勢。
- 按 MSCI 世界指數計算，康健護理業在期內雖上升，但仍相對拖累表現。康健護理供應與服務及生物科技分類行業的表現相對優於整體行業，但康健護理設備與用品、生命科學工具與服務及製藥分類行業表現落後。
- Global equities performed well in September amid generally upbeat news flow, adding to their strong year-to-date gains and propelling the major world indexes to a series of new all-time highs. Investor sentiment remained robust, reflecting the combination of positive global growth, healthy corporate earnings, and interest rate cuts by the US Federal Reserve (Fed) and other central banks. The US was a key driver of the positive returns, with the technology sector performing particularly well amid ongoing enthusiasm about artificial intelligence (AI). In addition, the US Fed's quarter-point rate cut raised hopes that several more reductions would be in store over the coming year. The gains were somewhat narrower overseas. Europe finished in positive territory but failed to keep pace with the US, primarily as a result of a downturn in Germany. Developed Asia also lagged, with muted returns across the board. On the other hand, emerging markets experienced a meaningful rally and strongly outpaced their developed market peers, thanks in part to an impressive advance for China.
- The healthcare sector increased during the period but detracted, as measured by the MSCI World Index. The healthcare providers and services and biotechnology sub-sectors performed relative to the overall sector while the healthcare equipment and supplies, life sciences tools and services, and pharmaceuticals sub-sectors lagged.

資料來源：宏利人壽保險（國際）有限公司及宏利投資管理（香港）有限公司

Source: Manulife (International) Limited and Manulife Investment Management (Hong Kong) Limited

- 1 宏利人壽保險（國際）有限公司是於百慕達註冊成立之有限責任公司。
Manulife (International) Limited is incorporated in Bermuda with limited liability.
- 2 截至 2024 年 12 月 31 日 止財政年度的總費用比率。
Total expense ratio for financial period ended December 31, 2024.
- 3 有關「宏利（澳門）風險／回報指標」：
Notes for the Manulife (Macau) Risk/Return Meter:

1	低／1 Low / 1	- 在低風險下，旨在尋求短期的小幅度增長 - seeks to provide small short term growth with low risk exposure
2	低至中／2 Low to Medium / 2	- 在低至中風險下，旨在尋求中至長期的增長 - seeks to provide some medium to long term growth with low to medium risk exposure
3	中度／3 Medium / 3	- 在中度風險下，旨在尋求中至長期的資本增長 - seeks to provide some medium to long term growth of capital with medium risk exposure
4	中至高／4 Medium to High / 4	- 在中至高風險下，旨在尋求中至長期的資本增長 - seeks to provide medium to long term growth of capital with medium to high risk exposure
5	高／5 High / 5	- 在高風險下，旨在尋求長期的資本增長 - seeks to provide long term growth of capital with high risk exposure

「宏利（澳門）風險／回報指標」（「指標」）級別之標示乃基於與有關基金旗下投資項目相關的多項因素，包括資產類別及其相應的目標比重、覆蓋範圍及地域分佈，及有關市場過往的長期波幅和市場價值。指標內的不同級別是代表不同潛在風險／回報程度的一般歸類。

The level of the Manulife (Macau) Risk/Return Meter (the "Meter") assigned to each of the funds is based on a number of factors relating to their underlying investments, including types of asset classes and their respective target weightings, breadth and geographical diversification and historical long term volatility and capitalization of the relevant markets. Different levels in the Meter represent a general division of potential risk/return profiles.

投資越分散及相關資產穩定性越高，波幅也將相對較低。一般而言，預期投資回報越高，所須承擔的風險也越高。基金獲分配風險／回報程度之級別，是用以提示其相關投資項目的波幅。基金的風險越高，其升跌幅亦較風險較低的基金為高。

The greater the diversification and the more stable the underlying asset, the less volatility will be experienced. Generally, the greater the return you want to earn on your investments, the greater risk you have to assume. The assigned level of risk/return profile of a fund highlights the volatility of the relevant investments. The value of a fund with higher risk normally fluctuates to a greater extent than a fund with lower risk.

較高風險的基金波幅可能較大，長線而言，投資於較高風險的基金或可有較佳回報潛力。

While higher risk funds may be more volatile, over the long term a higher risk fund may have better potential for higher returns.

指標由宏利投資管理（香港）有限公司制定及定期檢討，並只供參考。指標不是一種財務工具，亦不應被依賴作為投資決定及選取基金的根據，或被用作代替獨立的專業建議。本公司並不會就任何投資分配及選取基金提供建議。您應該徵詢獨立的專業財務意見，本公司概不會就所載資料被視作為投資建議而引致的任何損失負責。

The Meter is developed and regularly reviewed by Manulife Investment Management (Hong Kong) Limited and is provided for reference only. It is not a financial tool and must not be relied upon to make any investment decisions and selection of funds or be used as a substitute for independent professional advice. Manulife does not provide advice regarding any investment allocations and selection of funds. You should seek independent professional financial advice. We are not responsible for any loss occasioned as a result of relying on such information as investment advice.

- 4 基金風險標記是以年度標準差表示，數據是根據過往三年之按月回報率計算，並計算至小數後兩個位。一般來說，年度標準差數值越大，基金的波幅／風險也將相對較高。基金風險標記會於該基金推出三年後提供。
The Fund Risk Indicator shows the annualized standard deviation based on the monthly rates of return of the fund over the past 3 years, and calculate to 2 decimal places. Generally, the greater the annualized standard deviation, the more volatile/risky the fund. The Fund Risk Indicator for the fund will be available 3 years after its launch date.
- 5 若退休基金的基金風險標記超出下列的內部參考指標，將於額外風險提示解釋超出內部參考指標的成因。
If the Fund Risk Indicator of a pension fund exceeds the internal reference benchmark listed below, the reason(s) for exceeding the internal reference benchmark will be provided in the Additional Risk Reminder.

風險程度 Fund Risk Level	內部參考指標 Internal Reference Benchmark
低 Low	基金風險標記 Fund Risk Indicator < 2.0%
低至中 Low to Medium	基金風險標記 Fund Risk Indicator < 5.0%
中 Medium	基金風險標記 Fund Risk Indicator < 10.0%
中至高 Medium to High	基金風險標記 Fund Risk Indicator < 15.0%
高 High	-

- 6 基金表現是分別按港元及澳門元的單位價格計算。港元單位價格是以基金的資產淨值計算，並已扣除適用收費及費用。澳門元單位價格是以港元單位價格換算所得。

Fund performance is calculated based on the unit prices in Hong Kong dollar and Macau pataca respectively. The unit price in Hong Kong dollar is calculated based on the NAV (net asset value) of the funds and is net of applicable fees and charges. The unit price in Macau pataca is converted from the unit price in Hong Kong dollar.

7 由於進位數關係，總額可能並不相等於 100%。
Due to rounding, the total may not be equal to 100%.

8 「基金十大投資項目」列出基金投資組合內的十大證券組合（不包括現金及其他）。基金投資組合可能持有少於十項證券組合。
"Fund Top 10 Portfolio Holdings" lists out the largest 10 security holdings (i.e. not including cash and others) of the fund portfolio. The fund portfolio may have less than 10 security holdings.

9 此基金僅限於宏利中央積金內提供，並於 2025 年 7 月 2 日推出。
This fund is exclusively available under the Manulife Central Provident Fund and was launched on July 2, 2025.

10 「宏利（澳門）退休金計劃」及所提供之開放式退休基金只適用於澳門特別行政區。有關「宏利（澳門）退休金計劃」及其開放式退休基金的詳情，包括計劃規則、基金投資政策、風險因素、費用及收費等，可經右列二維碼參閱「集成協議」、「管理規章」、「參與協議」、產品手冊、基金便覽及有關公告。

The Manulife (Macau) Pension Fund Scheme and the open pension funds offered are available only in the Macau Special Administrative Region. Please refer to the Master Agreement, Management Regulation, Participation Agreement, product brochure, fund fact sheets and relevant notices for details of the Manulife (Macau) Pension Scheme and its open pension funds, including scheme rules, investment policies of the funds, risk factors, fees and charges, etc. via the QR code.



中文



English

11 「宏利中央積金」及所提供之開放式退休基金只適用於澳門特別行政區。有關「宏利中央積金」及其開放式退休基金的詳情、公積金共同計劃、公積金個人計劃，可經右列二維碼參閱「服務協議」、「設立合同」、「管理規章」、產品小冊子、基金便覽及有關公告。

The Manulife Central Provident Fund (CPF) and the open pension funds offered are available only in the Macau Special Administrative Region. Please refer to the Service Agreement, Establishment Contract, Management Regulation, product brochure, fund fact sheets and relevant notices for details of the Manulife Central Provident Fund (CPF) and its open pension funds via the QR code.



中文



English

警告 : **基金單位價格可升可跌。所載數據僅供參考而過往的基金表現不能作為日後表現的指標。投資帶有風險。** 本刊物所載任何資訊不應依賴作為投資建議，或視作代替詳細之投資建議，又或者視為代替個別情況之詳細投資建議。

註 : **所有基金之表現資料皆由相關基金旗下投資項目的投資經理提供。所有基金報價均已扣除適用收費及費用。**

WARNING : **Unit prices may fall as well as rise. The figures are for reference only and past performance is not indicative of future performance. Investment involves risks.** No information contained in this publication should be relied upon as investment advice or regarded as a substitute for detailed investment advice or regarded as a substitute for detailed investment advice in individual cases.

Note : **The performance information of all funds is provided by the investment manager(s) of the underlying funds of the respective funds. All unit prices declared are net of applicable fees and charges.**

若閣下對本刊物內容的含義及影響有任何疑問，應徵詢獨立專業人士之意見。

If you are in doubt about the meaning and/or effect of the contents of this publication, you should seek independent professional advice.

如欲參閱宏利之私隱政策，閣下可瀏覽宏利網站，網址為 www.manulife.com.hk。閣下並可要求宏利避免使用閣下的個人資料作直接促銷用途，如有此需要，請致函宏利的個人資料保密主任，地址為澳門新馬路 61 號永光廣場十四樓 A，或致電客戶服務熱線 (853) 8398 0383。

To view our Privacy Policy, you can go to our website at www.manulife.com.hk. You may also request Manulife not to use your personal information for direct marketing purpose by writing to our Privacy Officer at Avenida De Almeida Ribeiro No. 61, Circle Square, 14 andar A, Macau or by calling our Customer Service Hotline at (853) 8398 0383.

此基金概覽報導宏利中央積金 / 宏利（澳門）退休金計劃內各基金的最新走勢，並可在宏利網站 www.manulife.com.hk 下載，或致電成員服務熱線(853) 8398 0383。

This Fund Fact Sheet provides fund performance updates for Manulife Central Provident Fund / Manulife (Macau) Pension Fund Scheme and you can download it at www.manulife.com.hk, or by calling our Member Service Hotline at (853) 8398 0383.

由宏利人壽保險（國際）有限公司（於百慕達註冊成立之有限責任公司）刊發。地址：澳門新馬路 61 號永光廣場十四樓 A。

Issued by Manulife (International) Limited (Incorporated in Bermuda with limited liability). Address: Avenida De Almeida Ribeiro No. 61, Circle Square, 14 andar A, Macau.